Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28375820 | 0.85 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL9498879 | 0.80 | KMT2A (0.44) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL8236718 | 0.79 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL17753728 | 0.79 | KMT2A (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL7037298 | 0.79 | KMT2A (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| Hydrochloric Acid SCHEMBL2524994 | 0.77 | KMT2A (0.53) | KMT2AEPHX2CASP3TLR2 | |
| Bromide SCHEMBL15640173 | 0.77 | KMT2A (0.53) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL6788808 | 0.76 | KMT2A (0.52) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL28335815 | 0.76 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28758363 | 0.76 | KMT2A (0.54) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1481000-B1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20030036501-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS LLC | 2003-02-20 | — | — | US | disclosed |
| WO-2002008187-A9 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME LLC | 2002-10-31 | — | — | US | disclosed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6376649-B1 | REACTING A N-TERMINALLY BLOCKED AMINOALDEHYDE WITH AN ISONITRILE AND A CARBOXYLIC ACID TO GIVE AN AMINO-ALPHA-ACYLOXYCARBOXAMIDE; REMOVING THE ACYLOXY GROUP, OR REMOVING THE PROTECTING GROUP GIVE THE DERIVATIVE. | CORVAS INTERNATIONAL, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2002008244-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008187-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008256-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1140854-A2 | METHODS FOR THE SYNTHESIS OF ALPHA-HYDROXY-BETA-AMINO ACID AND AMIDE DERIVATIVES | CORVAS INTERNATIONAL, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035868-A2 | METHODS FOR THE SYNTHESIS OF ALPHA-HYDROXY-BETA-AMINO ACID AND AMIDE DERIVATIVES | CORVAS INTERNATIONAL, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, TMPRSS15, TMPRSS11D | KMT2A 3141/4885FABP5 1652/4885FABP7 2739/4885 |
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, HAVCR2 | KMT2A 3594/4885FABP5 1716/4885FABP7 2704/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | KMT2A 3449/4885FABP5 1975/4885FABP7 2841/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | KMT2A 3449/4885FABP5 1975/4885FABP7 2841/4885 |
| US-20030036501-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, TMPRSS15 | KMT2A 3584/4885FABP5 1688/4885FABP7 2721/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | KMT2A 3449/4885FABP5 1975/4885FABP7 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.